Semax — Research Summary

Research Use Only · Not for Human or Veterinary Use

Synthetic ACTH(4-10) analog studied for nootropic and neuroprotective research a

Semax

An evidence summary of published preclinical research on Semax. This page is educational and summarizes findings reported in third-party scientific literature. No claims are made regarding safety or efficacy in humans.

Molecular Data

FORMULA C37H51N9O10S
MOLECULAR WEIGHT 813.93 g/mol
SEQUENCE Met-Glu-His-Phe-Pro-Gly-Pro

Compound Overview

Semax is a synthetic peptide analog of ACTH (adrenocorticotropic hormone), specifically the 4-10 fragment with an added Pro-Gly-Pro C-terminal tripeptide for enhanced stability. Originally developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been the subject of extensive research for its nootropic and neuroprotective properties. It is one of the most studied cognitive enhancement peptides in peer-reviewed literature.

Reported Mechanism (Preclinical)

Semax exerts its effects through multiple neurological pathways: it increases BDNF (brain-derived neurotrophic factor) expression, modulates serotonergic and dopaminergic systems, enhances NGF (nerve growth factor) synthesis, and activates melanocortin receptors (MC3R and MC4R). Research suggests it may improve synaptic plasticity, enhance memory consolidation, and provide neuroprotection against oxidative stress and excitotoxicity.

Mechanisms described above are reported in preclinical (animal and in vitro) literature and have not been established for human use.

Key Research Highlights

  • Increased BDNF mRNA expression in rat hippocampus and basal forebrain
  • Demonstrated neuroprotective effects in ischemic brain injury models
  • Improved cognitive performance in learning and memory paradigms in animal models
  • Enhanced attention and executive function markers in preclinical behavioral tests
  • Showed anxiolytic effects without sedation in elevated plus maze models

Published References

  1. Semax affects BDNF and trkB expression in rat brain
    Brain Res, 2007
  2. Neuroprotective effects of Semax in cerebral ischemia
    Neurosci Behav Physiol, 2005
  3. Semax: mechanisms of action and clinical applications
    CNS Drug Rev, 2005

Available for Research

Lab-tested, third-party COA published, U.S. ships same day.

View Product · Semax View COA Library
Compliance Notice: American Peptides products are sold strictly for laboratory and academic research purposes only. They are not intended for human or veterinary consumption, diagnosis, treatment, or prevention of any disease. All content on this page is educational in nature, summarizes findings from preclinical literature, and does not constitute medical advice or product claims. Researchers are responsible for handling these compounds in accordance with their institution's safety protocols and applicable laws.